INTEGRATED STRATEGIES FOR THE MANAGEMENT OF INSOMNIA

Abstract

One of the most prevalent sleep problems in the world is insomnia.1 The number of patients seeking pharmacological treatment for insomnia is steadily rising due to its increased prevalence. Unwanted anticholinergic side effects have restricted the long-standing use of tricyclic antidepressants for insomnia. Clinical trials for the hypocretin/orexin antagonist MK4035 are now underway. The effectiveness of serotonin antagonists and inverse agonists in treating insomnia is being studied; however, more recent studies looking at different mechanisms of action indicate that drugs that affect the histaminergic, serotonergic, hypocretin/orexin, and possibly gamma-aminobutyric acid B systems may be useful in treating insomnia. The management of insomnia is the main topic of this systematic review. Insomnia's primary causes and risk factors are examined, such  as well as the requirements for a proper diagnosis. The Creative Commons Attribution License governs the distribution of this open access article (https: Reviewing the operational definitions and treatment of persistent insomnia is the goal of this paper. The findings of a computerized search on Pub conducted between 1980 and January 2009 were summarized. Chronic insomnia can be managed in several ways. It must be defined and distinguished from other co-morbid mental illnesses before therapy may begin.